Oropharynx cancer in the US: Racial disparities in stage at presentation.

J James Suggitt (Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI) Y Yingzhi Wu (Memorial Sloan Kettering Cancer Center, New York, NY) A Annu Singh (Memorial Sloan Kettering Cancer Center, New York, NY) E Erin Jay Garbes Feliciano (Ateneo School of Medicine and Public Health, Ateneo de Manila University, Pasig City, Philippines) J Jennifer Ma (Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY) S Sean Matthew McBride (Memorial Sloan Kettering Cancer Center, New York, NY) C Cherry Estilo (Memorial Sloan Kettering Cancer Center, New York, NY) N Nancy Y. Lee E Edward Christopher Dee

Abstract

e13766 Background: Global occurrence of oropharynx cancer (OPC) varies greatly. While rare in the US, the diverse nature of the US clinical environment – where patients face intersectional disparities in access across the cancer continuum – requires a greater understanding of existing disparities in OPC. As such, this study explored the difference in stage at presentation of OPC, focusing on AA patient subpopulations. Methods: Patients with OPC were identified from the National Cancer Database (2004 to 2021), allowing for disaggregation by race/ethnicity and analysis of Asian American (AA) and other subgroups. Multivariable ordinal logistic regression models (adjusting for demographic and socioeconomic factors) defined adjusted odds ratios (aORs, higher aOR represents greater risk of advanced OPC). Results: Among the 30635 patients, the majority were white (25979, 84.8%) and Black (3738, 12.2%). Among the majority populations, white patients were more likely to be insured (χ2 P < .0001) and live outside of low-income zip codes (χ2 P < .0001), but Black patients were more likely to be uninsured (χ2 P < .0001) and live in lower-income zip codes (χ2 P < .0001). The population was heterogeneous in income and insurance status. Among patients without insurance, 55.9% presented with distant metastatic disease (37.0% for private insurance, 52.6% for Medicaid, and 35.9% for Medicare), while 50.5% of patients in the lowest income zip codes presented with distant metastatic disease, versus 42.3% for the highest income zip codes (P < .01 for all). Prior to disaggregation, distant metastatic disease comprised 37.8% of cases in white patients (ref), 51.2% in Black patients (aOR 1.50, P < .0001), 41.7% in Native American patients (aOR 1.49, P > .05), 41.4% in AA patients (aOR 1.62, P = .0009), and 33.3% in Native Hawaiian and other Pacific Islander patients (aOR 0.71, P > .05). After disaggregation, rates of distant metastatic disease at presentation were greatest (≥50%) among Laotian (100%), Kampuchean (100%), Japanese (51.7%, aOR 1.60, P > .05), Black (51.2%, aOR 1.50, P < .0001), and Hmong (50%) patients. Rates of presentation with distant metastatic disease were lower than whites in Korean (37.5%, aOR 1.35, P > .05), Vietnamese (36.7%, aOR 0.90, P > .05), Native Hawaiian (36.4%, aOR 2.83, P > .05), and other Pacific Islander (11.1%, aOR 0.49, P < .0001) patients. Notably, Asian Indian & Pakistani patients were at increased risk of distant metastatic disease at presentation (45.9%, aOR 2.06, P = .03). Conclusions: While the vast majority of OPC patients in the US were not from minoritized groups, distant metastatic disease at presentation was most common in AA subgroup (Laotian, Kampuchean, Japanese, and Hmong) and Black patients, even when adjusted for social determinants of health. This follows previously established trends of disparities in head and neck cancer, and support engagement with minority populations to increase awareness of OPC.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (9)

J

James Suggitt

Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI

Y

Yingzhi Wu

Memorial Sloan Kettering Cancer Center, New York, NY

A

Annu Singh

Memorial Sloan Kettering Cancer Center, New York, NY

E

Erin Jay Garbes Feliciano

Ateneo School of Medicine and Public Health, Ateneo de Manila University, Pasig City, Philippines

J

Jennifer Ma

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

S

Sean Matthew McBride

Memorial Sloan Kettering Cancer Center, New York, NY

C

Cherry Estilo

Memorial Sloan Kettering Cancer Center, New York, NY

N

Nancy Y. Lee

E

Edward Christopher Dee